Published in Methods Mol Biol on January 01, 2009
Aptamers as therapeutics. Nat Rev Drug Discov (2010) 5.36
Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity. Chem Biol (2015) 1.53
PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem (2013) 1.42
Fluorescence-activated cell sorting for aptamer SELEX with cell mixtures. Nat Protoc (2010) 1.28
New Technologies Provide Quantum Changes in the Scale, Speed, and Success of SELEX Methods and Aptamer Characterization. Mol Ther Nucleic Acids (2014) 1.21
Aptamer-targeted cell-specific RNA interference. Silence (2010) 1.17
Targeting microRNAs in obesity. Expert Opin Ther Targets (2009) 1.14
Differential SELEX in human glioma cell lines. PLoS One (2009) 1.13
GCPII imaging and cancer. Curr Med Chem (2012) 1.12
Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents. Mol Ther Nucleic Acids (2014) 1.09
A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death. PLoS One (2011) 1.08
Entropy-driven one-step formation of Phi29 pRNA 3WJ from three RNA fragments. Biochemistry (2014) 0.91
Cell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cells. Methods Mol Biol (2015) 0.87
Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells. Nucleic Acid Ther (2012) 0.87
PTK7: a new biomarker for immunophenotypic characterization of maturing T cells and T cell acute lymphoblastic leukemia. Leuk Res (2012) 0.86
Identification of RNA aptamers that internalize into HPV-16 E6/E7 transformed tonsillar epithelial cells. Virology (2013) 0.86
Developing aptamer probes for acute myelogenous leukemia detection and surface protein biomarker discovery. J Hematol Oncol (2014) 0.85
Nucleic acids in human glioma treatment: innovative approaches and recent results. J Signal Transduct (2012) 0.83
Selection of aptamers for mature white adipocytes by cell SELEX using flow cytometry. PLoS One (2014) 0.80
RNA Nanoparticles Derived from Three-Way Junction of Phi29 Motor pRNA Are Resistant to I-125 and Cs-131 Radiation. Nucleic Acid Ther (2015) 0.79
Aptamers and their potential to selectively target aspects of EGF, Wnt/β-catenin and TGFβ-smad family signaling. Int J Mol Sci (2013) 0.78
Specific Delivery of MiRNA for High Efficient Inhibition of Prostate Cancer by RNA Nanotechnology. Mol Ther (2016) 0.78
Development of Phosphorothioate DNA and DNA Thioaptamers. Biomedicines (2017) 0.76
Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome. Oncotarget (2016) 0.75
Mechanism of three-component collision to produce ultrastable pRNA three-way junction of Phi29 DNA-packaging motor by kinetic assessment. RNA (2016) 0.75
Smooth Muscle Cell-targeted RNA Aptamer Inhibits Neointimal Formation. Mol Ther (2016) 0.75
Beyond adhesion: emerging roles for integrins in control of the tumor microenvironment. F1000Res (2017) 0.75
Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science (1990) 35.96
In vitro selection of RNA molecules that bind specific ligands. Nature (1990) 30.19
Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature (1992) 7.61
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A (2006) 6.90
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol (2005) 6.40
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol (2006) 6.30
The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer (2004) 5.47
Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res (2002) 4.16
Aptamer mediated siRNA delivery. Nucleic Acids Res (2006) 2.77
Retracted Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol (2005) 2.77
Nucleic Acid Selection and the Challenge of Combinatorial Chemistry. Chem Rev (1997) 2.59
High affinity ligands from in vitro selection: complex targets. Proc Natl Acad Sci U S A (1998) 2.30
The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev (2001) 2.05
The RET proto-oncogene in human cancers. Oncogene (2000) 1.98
The RET receptor: function in development and dysfunction in congenital malformation. Trends Genet (2001) 1.67
Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet (2000) 1.61
Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proc Natl Acad Sci U S A (2003) 1.54
Combinatorial selection of high affinity RNA ligands to live African trypanosomes. Nucleic Acids Res (1999) 1.35
Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role for 2'-hydroxyl uridines in immune responses. Eur J Immunol (2006) 1.27
RET and neuroendocrine tumors. Cancer Lett (2004) 1.27
Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum Gene Ther (2006) 1.26
RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family. Nucleic Acids Res (2004) 1.12
The RET proto-oncogene: a potential target for molecular cancer therapy. Trends Mol Med (2004) 1.03
Targeted inhibition of alphavbeta3 integrin with an RNA aptamer impairs endothelial cell growth and survival. Biochem Biophys Res Commun (2005) 1.00
Comparison of different strategies to select aptamers against a transmembrane protein target. Oligonucleotides (2006) 0.93
Intramers and aptamers: applications in protein-function analyses and potential for drug screening. Chembiochem (2005) 0.91
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol (2006) 6.30
Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron (2009) 4.98
Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol (2009) 3.78
E2Fs link the control of G1/S and G2/M transcription. EMBO J (2004) 2.81
Retracted Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol (2005) 2.77
Zinc-mediated transactivation of TrkB potentiates the hippocampal mossy fiber-CA3 pyramid synapse. Neuron (2008) 2.64
Conditional deletion of TrkB but not BDNF prevents epileptogenesis in the kindling model. Neuron (2004) 2.38
Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J Clin Invest (2008) 2.18
Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature (2010) 1.73
Exome sequencing followed by large-scale genotyping fails to identify single rare variants of large effect in idiopathic generalized epilepsy. Am J Hum Genet (2012) 1.72
Rapid identification of cell-specific, internalizing RNA aptamers with bioinformatics analyses of a cell-based aptamer selection. PLoS One (2012) 1.60
Therapeutic applications of DNA and RNA aptamers. Oligonucleotides (2009) 1.59
Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res (2012) 1.47
Increased expression of brain-derived neurotrophic factor induces formation of basal dendrites and axonal branching in dentate granule cells in hippocampal explant cultures. J Neurosci (2002) 1.31
Vesicular zinc promotes presynaptic and inhibits postsynaptic long-term potentiation of mossy fiber-CA3 synapse. Neuron (2011) 1.29
Targeting cancer cells with nucleic acid aptamers. Trends Biotechnol (2010) 1.26
Nucleic acid aptamers in cancer medicine. FEBS Lett (2002) 1.22
Structural plasticity of dentate granule cell mossy fibers during the development of limbic epilepsy. Hippocampus (2010) 1.21
Localization of brain-derived neurotrophic factor to distinct terminals of mossy fiber axons implies regulation of both excitation and feedforward inhibition of CA3 pyramidal cells. J Neurosci (2004) 1.20
Ischemic stroke: "acidotoxicity" is a perpetrator. Cell (2004) 1.19
Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers. Mol Ther (2011) 1.17
Formation of complement membrane attack complex in mammalian cerebral cortex evokes seizures and neurodegeneration. J Neurosci (2003) 1.17
Transient inhibition of TrkB kinase after status epilepticus prevents development of temporal lobe epilepsy. Neuron (2013) 1.16
Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. Nucleic Acid Ther (2011) 1.16
Nucleotide bias observed with a short SELEX RNA aptamer library. Nucleic Acid Ther (2011) 1.15
Immunohistochemical evidence of seizure-induced activation of trkB receptors in the mossy fiber pathway of adult mouse hippocampus. J Neurosci (2002) 1.15
RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin. Mol Ther (2007) 1.14
Targeting Axl with an high-affinity inhibitory aptamer. Mol Ther (2012) 1.14
Differential SELEX in human glioma cell lines. PLoS One (2009) 1.13
Plasticity of both excitatory and inhibitory synapses is associated with seizures induced by removal of chronic blockade of activity in cultured hippocampus. J Neurophysiol (2006) 1.13
Mutual regulation of Src family kinases and the neurotrophin receptor TrkB. J Biol Chem (2010) 1.10
Current progress on aptamer-targeted oligonucleotide therapeutics. Ther Deliv (2013) 1.09
A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death. PLoS One (2011) 1.08
New insight into clinical development of nucleic acid aptamers. Discov Med (2011) 1.07
Deficiency of asparagine synthetase causes congenital microcephaly and a progressive form of encephalopathy. Neuron (2013) 1.06
Intracellular delivery of RNA-based therapeutics using aptamers. Ther Deliv (2010) 1.05
Disruption of TrkB-mediated phospholipase Cgamma signaling inhibits limbic epileptogenesis. J Neurosci (2010) 1.04
A cross-talk between TrkB and Ret tyrosine kinases receptors mediates neuroblastoma cells differentiation. PLoS One (2008) 1.03
Temporal control of cell cycle gene expression mediated by E2F transcription factors. Cell Cycle (2005) 1.03
In vivo profile of ICA-27243 [N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide], a potent and selective KCNQ2/Q3 (Kv7.2/Kv7.3) activator in rodent anticonvulsant models. J Pharmacol Exp Ther (2008) 1.02
A galactosylceramide binding domain is involved in trafficking of CLN3 from Golgi to rafts via recycling endosomes. Pediatr Res (2004) 1.02
TrkB signaling is required for behavioral sensitization and conditioned place preference induced by a single injection of cocaine. Neuropharmacology (2010) 1.01
Targeted inhibition of alphavbeta3 integrin with an RNA aptamer impairs endothelial cell growth and survival. Biochem Biophys Res Commun (2005) 1.00
GDNF selectively induces microglial activation and neuronal survival in CA1/CA3 hippocampal regions exposed to NMDA insult through Ret/ERK signalling. PLoS One (2009) 0.99
Altered morphology of hippocampal dentate granule cell presynaptic and postsynaptic terminals following conditional deletion of TrkB. Hippocampus (2008) 0.99
Synthesis and radiolabeling of chelator-RNA aptamer bioconjugates with copper-64 for targeted molecular imaging. Bioorg Med Chem (2011) 0.98
Contributions of mossy fiber and CA1 pyramidal cell sprouting to dentate granule cell hyperexcitability in kainic acid-treated hippocampal slice cultures. J Neurophysiol (2004) 0.96
Temporal specific patterns of semaphorin gene expression in rat brain after kainic acid-induced status epilepticus. Hippocampus (2003) 0.92
Degradation of nuclease-stabilized RNA oligonucleotides in Mycoplasma-contaminated cell culture media. Nucleic Acid Ther (2012) 0.92
Ontogeny of seizure-induced increases in BDNF immunoreactivity and TrkB receptor activation in rat hippocampus. Hippocampus (2004) 0.92
5'-End RET splicing: absence of variants in normal tissues and intron retention in pheochromocytomas. Oncology (2002) 0.92
The soluble ectodomain of RetC634Y inhibits both the wild-type and the constitutively active Ret. Biochem J (2003) 0.90
Neuroprotective effects of reactive oxygen species mediated by BDNF-independent activation of TrkB. J Neurosci (2012) 0.90
Reduction of TrkB expression de novo in the adult mouse impairs epileptogenesis in the kindling model. Hippocampus (2010) 0.88
Cell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cells. Methods Mol Biol (2015) 0.87
An autocrine loop involving ret and glial cell-derived neurotrophic factor mediates retinoic acid-induced neuroblastoma cell differentiation. Mol Cancer Res (2006) 0.87
RNA aptamer-based functional ligands of the neurotrophin receptor, TrkB. Mol Pharmacol (2012) 0.87
Methods for Evaluating Cell-Specific, Cell-Internalizing RNA Aptamers. Pharmaceuticals (Basel) (2013) 0.86
Identification of RNA aptamers that internalize into HPV-16 E6/E7 transformed tonsillar epithelial cells. Virology (2013) 0.86
Does epileptiform activity contribute to cognitive impairment in Alzheimer's disease? Neuron (2007) 0.85
Direct interactions among Ret, GDNF and GFRalpha1 molecules reveal new insights into the assembly of a functional three-protein complex. Cell Signal (2004) 0.84
Nucleic acid-based aptamers as promising therapeutics in neoplastic diseases. Methods Mol Biol (2007) 0.84
The cellular and synaptic location of activated TrkB in mouse hippocampus during limbic epileptogenesis. J Comp Neurol (2013) 0.83
Elevated expression of the tyrosine phosphatase SHP-1 defines a subset of high-grade breast tumors. Oncology (2010) 0.83
Shp2 in PC12 cells: NGF versus EGF signalling. Cell Signal (2007) 0.81
Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists. J Med Chem (2008) 0.81
A locus for generalized tonic-clonic seizure susceptibility maps to chromosome 10q25-q26. Ann Neurol (2005) 0.81
Morphological changes among hippocampal dentate granule cells exposed to early kindling-epileptogenesis. Hippocampus (2013) 0.80
Impairment of kindling development in phospholipase Cγ1 heterozygous mice. Epilepsia (2014) 0.79
Antiseizure effects of TrkB kinase inhibition. Epilepsia (2014) 0.79
The isolectin IB4 binds RET receptor tyrosine kinase in microglia. J Neurochem (2013) 0.79
The auxiliary subunit KChIP2 is an essential regulator of homeostatic excitability. J Biol Chem (2013) 0.79
B cells and epilepsy: the odd couple. Neurology (2002) 0.78
The Shp-1 and Shp-2, tyrosine phosphatases, are recruited on cell membrane in two distinct molecular complexes including Ret oncogenes. Cell Signal (2004) 0.78
Fleeting activation of ionotropic glutamate receptors sensitizes cortical neurons to complement attack. Neuron (2002) 0.78
Expression of GFRalpha1 receptor splicing variants with different biochemical properties is modulated during kidney development. Cell Signal (2004) 0.77
Translation of an integral membrane protein in distal dendrites of hippocampal neurons. Eur J Neurosci (2005) 0.77
Inhibiting glycolysis to reduce seizures: how it might work. Nat Neurosci (2006) 0.77
Vagus nerve stimulation elevates seizure threshold in the kindling model. Epilepsia (2012) 0.76
A regulatory mechanism involving TBP-1/Tat-Binding Protein 1 and Akt/PKB in the control of cell proliferation. PLoS One (2011) 0.76
Fas(t) balls and Lou Gehrig disease. A clue to selective vulnerability of motor neurons? Neuron (2002) 0.76
Aligning animal models with clinical epilepsy: where to begin? Adv Exp Med Biol (2014) 0.76
In search of the ever-elusive positive endozepine. Neuron (2013) 0.75
Conditional deletion of TrkC does not modify limbic epileptogenesis. Epilepsy Res (2012) 0.75
Impaired volume regulation is the mechanism of excitotoxic sensitization to complement. J Neurosci (2006) 0.75